Johnson & Johnson has acquired Amic, a Swedish developer of in vitro diagnostic technologies for use in point-of-care and near-patient settings. No financial terms were disclosed. Amic had raised around $8.5 million in VC funding since 2002, from firms like InnovationsKapital and Investor Growth Capital.
Johnson & Johnson Nordic AB, a Johnson & Johnson company, today announced the acquisition of Amic, a privately held Swedish developer of in vitro diagnostic (IVD) technologies for use in Point-of-Care (POC) and near-patient settings (outside the physical facilities of the clinical laboratory). The acquisition will provide Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company, with access to a high performance technology platform